UroToday

PSMA and Beyond 2025: How to Crush a PSMA PET Report: Guidelines and Scoring Systems

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured a PSMA session and a presentation by Dr. Phillip Kuo discussing guidelines and scoring systems of a PSMA PET report. Dr. Kuo started his ...
UroToday

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday

2026 American Society of Clinical Oncology (ASCO)

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

ASCO GU 2022: Phase 1b Study of Tarlatamab, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE Immune Therapy) Targeting DLL3, in De Novo or Treatment Emergent ...

(UroToday.com) The 2022 GU ASCO Annual meeting included a prostate cancer trials in progress session featuring Dr. Rahul Aggarwal presenting a phase 1b study of tarlatamab, a half-life extended ...
UroToday

ASCO GU 2026: Discussant: Improving Outcomes for Radiotherapy

(UroToday.com) The 2026 GU ASCO annual meeting featured a prostate cancer session and a discussant presentation by Dr. Bridget Koontz, discussing two abstracts, “Hormone therapy use and duration with ...
UroToday

ESMO 2025: Disitamab Vedotin plus Toripalimab Versus Chemotherapy in First-Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) with HER2-Expression

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a presidential symposium. Dr. Jun Guo presented the results of a trial of disitamab vedotin + ...
UroToday

European Association of Urology Congress (EAU) 2025 Annual Meeting

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

PSMA and Beyond 2025: Beyond PSMA in Prostate Cancer: STEAP1, DLL3, and CD46

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured new developments in genitourinary radioligand therapy session and a presentation by Dr. Robert Flavell discussing STEAP1, DLL3, and CD46 ...
UroToday

EAU 2026: Treatment of High-grade NMIBC: Results from the VERSUS Study

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a surgical and non-surgical treatment of non muscle invasive bladder cancer session and a presentation by Dr.
UroToday

Adjuvant Radiotherapy After Cystectomy in Muscle-Invasive Bladder Cancer: Indications, Benefits and Remaining Challenges.

Bladder cancer accounts for nearly 600,000 new cases and over 200,000 deaths annually worldwide. Approximately 25% of diagnoses correspond to muscle-invasive disease ...
UroToday

Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer in a Prospective Statewide Collaborative

Randy A. Vince Jr., Ralph Jiang, Ji Qi, Jeffrey J. Tosoian, Rebecca Takele, Felix Y. Feng, Susan Linsell, Anna Johnson, Sughand Shetty, Patrick Hurley, David C ...
UroToday

PSMA and Beyond 2026: How PCWG4 Impacts Future Trials

(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. Michael Morris discussing how PCWG4 impacts future trials. Dr. Morris started his ...